

Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.0	87.7	(35.1-180.6)	Male	5	6.0	83.6	(26.9-195.1)
Female	3	2.0	nc	(nc-nc)	Female	6	4.2	142.9	(52.2-311.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.2	116.0	(42.4-252.5)
Female	39	30.1	129.5	(92.1-177.1)	Female	5	3.0	166.2	(53.5-387.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	10.4	76.8	(33.1-151.3)	Female	6	2.7	219.7	(80.2-478.3)
Female	12	6.6	180.9	(93.4-316.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.7	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	39	37.0	105.5	(75.0-144.3)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	3	0.6	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.7	nc	(nc-nc)
Male	9	5.1	176.1	(80.4-334.3)	<u>Testis</u>				
Female	4	2.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.4	nc	(nc-nc)	Male	5	2.2	225.2	(72.6-525.6)
Female	0	0.3	nc	(nc-nc)	Female	8	6.5	123.4	(53.1-243.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.2	nc	(nc-nc)	Female	6	7.1	84.4	(30.8-183.7)
Female	1	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	135	122.1	110.5	(92.7-130.8)
Male	3	2.8	nc	(nc-nc)	Female	119	93.2	127.7	(105.8-152.8)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	15.4	162.0	(104.8-239.2)					
Female	11	11.6	94.7	(47.2-169.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	22.7	114.5	(74.8-167.7)	Male	16	15.4	104.0	(59.4-168.9)
Female	6	8.4	71.1	(26.0-154.7)	Female	6	11.2	53.5	(19.6-116.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.6	130.2	(47.5-283.4)	Male	5	3.8	131.5	(42.4-306.9)
Female	2	3.6	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	20	13.4	149.0	(91.0-230.2)
Female	66	78.0	84.6	(65.4-107.7)	Female	11	10.6	103.9	(51.8-186.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	12	9.4	128.2	(66.2-223.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	27.9	82.5	(52.3-123.7)	Female	4	7.7	nc	(nc-nc)
Female	29	28.2	102.7	(68.8-147.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	7.4	94.6	(37.9-194.8)
Male	4	5.9	nc	(nc-nc)	Female	9	8.1	110.6	(50.5-210.0)
Female	0	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	95	83.0	114.5	(92.7-140.0)
Male	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.5	nc	(nc-nc)	Male	6	5.3	113.1	(41.3-246.2)
<u>Kidney & Renal Pelvis</u>					Female	5	3.3	151.7	(48.9-354.0)
Male	12	12.4	97.1	(50.1-169.6)	<u>Testis</u>				
Female	5	6.8	73.4	(23.7-171.3)	Male	6	3.9	153.1	(55.9-333.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.4	nc	(nc-nc)	Male	6	5.3	113.7	(41.5-247.4)
Female	1	0.9	nc	(nc-nc)	Female	10	13.6	73.6	(35.3-135.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	8.6	nc	(nc-nc)	Female	26	17.2	151.2	(98.7-221.6)
Female	7	6.4	110.1	(44.1-227.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	336	306.3	109.7	(98.3-122.1)
Male	6	6.7	89.9	(32.8-195.8)	Female	267	285.4	93.6	(82.7-105.5)
Female	2	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	54	40.7	132.5	(99.6-172.9)					
Female	42	41.7	100.6	(72.5-136.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.5	106.2	(45.7-209.3)	Male	4	5.5	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	6	4.5	133.4	(48.7-290.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.8	146.1	(58.5-300.9)
Female	34	32.9	103.3	(71.5-144.3)	Female	8	3.6	224.2	(96.5-441.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	9.7	92.4	(42.1-175.3)	Female	2	3.0	nc	(nc-nc)
Female	6	8.6	69.4	(25.4-151.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	2.5	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	43	30.9	139.4	(100.9-187.7)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.9	nc	(nc-nc)
Male	6	4.7	127.5	(46.6-277.6)	<u>Testis</u>				
Female	4	2.5	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	10	6.4	157.2	(75.3-289.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.0	202.2	(73.8-440.0)	Female	7	7.4	94.0	(37.7-193.7)
Female	3	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	116	109.5	106.0	(87.6-127.1)
Male	0	2.5	nc	(nc-nc)	Female	125	105.6	118.4	(98.5-141.0)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	14.2	77.7	(38.7-139.0)					
Female	20	13.8	145.1	(88.6-224.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	8	6.0	134.0	(57.7-264.0)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.5	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	3	0.5	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	12	7.2	167.5	(86.4-292.6)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	0.6	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	33	23.9	138.1	(95.0-193.9)
Male	0	0.5	nc	(nc-nc)	Female	28	20.5	136.4	(90.6-197.1)
Female	0	0.2	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	1	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	2.8	283.3	(122.0-558.2)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	42.3	111.0	(81.6-147.7)	Male	32	26.9	119.0	(81.4-168.0)
Female	13	14.0	92.6	(49.2-158.3)	Female	29	19.7	147.3	(98.6-211.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	7.3	177.9	(94.6-304.3)	Male	5	7.0	71.7	(23.1-167.3)
Female	5	6.0	83.2	(26.8-194.2)	Female	5	5.1	97.8	(31.5-228.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	22	23.2	94.8	(59.4-143.5)
Female	122	149.5	81.6	(67.8-97.5)	Female	23	18.2	126.3	(80.1-189.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	5.4	130.2	(52.2-268.3)	Male	19	16.6	114.3	(68.8-178.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	40	50.5	79.1	(56.5-107.8)	Female	9	14.2	63.4	(28.9-120.3)
Female	50	45.0	111.1	(82.5-146.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	13.7	65.7	(30.0-124.8)
Male	10	11.2	89.4	(42.8-164.4)	Female	15	13.1	114.4	(64.0-188.6)
Female	2	2.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	143	164.7	86.8	(73.2-102.3)
Male	3	2.8	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.4	nc	(nc-nc)	Male	11	9.8	112.3	(56.0-200.9)
<u>Kidney & Renal Pelvis</u>					Female	7	5.1	138.3	(55.4-285.0)
Male	21	22.4	93.6	(57.9-143.1)	<u>Testis</u>				
Female	18	12.4	145.3	(86.1-229.7)	Male	7	3.9	177.3	(71.0-365.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	6.5	137.8	(62.9-261.7)	Male	4	8.2	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	30	25.0	120.0	(80.9-171.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	14.7	102.1	(57.1-168.5)	Female	28	35.4	79.1	(52.5-114.3)
Female	5	9.9	50.4	(16.2-117.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	548	565.5	96.9	(89.0-105.4)
Male	13	12.2	106.9	(56.9-182.8)	Female	516	509.9	101.2	(92.7-110.3)
Female	5	3.8	129.9	(41.9-303.1)					
<u>Lung and Bronchus</u>									
Male	85	78.4	108.4	(86.6-134.0)					
Female	88	74.7	117.7	(94.4-145.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.3	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	5.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	12	18.2	66.1	(34.1-115.5)
Male	0	0.4	nc	(nc-nc)	Female	11	14.7	75.0	(37.4-134.2)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	2.5	nc	(nc-nc)					
Female	0	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	0	0.7	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	13.8	87.0	(44.9-151.9)	Male	6	10.1	59.3	(21.6-129.0)
Female	2	5.0	nc	(nc-nc)	Female	13	8.8	148.1	(78.8-253.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.2	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	8.7	92.1	(39.7-181.6)
Female	69	60.5	114.0	(88.7-144.3)	Female	10	7.0	142.9	(68.4-262.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	7	6.5	107.6	(43.1-221.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	17.3	57.8	(27.7-106.3)	Female	7	5.6	124.5	(49.9-256.5)
Female	22	16.6	132.5	(83.0-200.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	4.6	172.8	(74.4-340.5)
Male	10	4.0	250.8	(120.1-461.2)	Female	3	4.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	62	58.7	105.7	(81.0-135.4)
Male	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.8	nc	(nc-nc)
Male	11	8.5	129.1	(64.4-231.1)	<u>Testis</u>				
Female	10	4.9	205.8	(98.5-378.5)	Male	3	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.3	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	7	12.7	55.2	(22.1-113.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	5.4	165.7	(75.6-314.6)	Female	16	13.7	117.1	(66.9-190.2)
Female	6	4.2	141.4	(51.6-307.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	200	202.5	98.8	(85.5-113.4)
Male	3	4.6	nc	(nc-nc)	Female	219	202.1	108.3	(94.5-123.7)
Female	2	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	26.3	87.4	(55.4-131.1)					
Female	31	27.0	115.0	(78.1-163.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.6	75.3	(24.3-175.6)	Male	2	4.6	nc	(nc-nc)
Female	7	2.5	280.6	(112.4-578.2)	Female	3	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	28	28.2	99.2	(65.9-143.4)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	8.3	108.4	(49.5-205.8)	Female	2	2.6	nc	(nc-nc)
Female	5	8.2	61.0	(19.7-142.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.2	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	27.7	86.7	(55.6-129.1)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.9	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	5.0	100.5	(32.4-234.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.4	nc	(nc-nc)	Female	11	6.4	171.4	(85.4-306.7)
Female	0	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	81	94.5	85.7	(68.0-106.5)
Male	2	2.1	nc	(nc-nc)	Female	81	94.8	85.5	(67.9-106.2)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	12.9	108.9	(59.5-182.8)					
Female	8	13.7	58.5	(25.2-115.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	8	7.5	107.3	(46.2-211.4)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	1.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	7	7.1	99.2	(39.7-204.4)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	20	23.1	86.8	(53.0-134.0)
Male	0	0.5	nc	(nc-nc)	Female	22	25.2	87.3	(54.7-132.1)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	3.0	nc	(nc-nc)					
Female	3	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	12.2	74.0	(33.7-140.4)	Male	12	7.3	163.6	(84.4-285.8)
Female	6	4.6	131.2	(47.9-285.6)	Female	9	5.5	163.8	(74.7-310.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.9	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.3	78.8	(25.4-183.8)
Female	47	41.1	114.2	(83.9-151.9)	Female	2	5.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	14.1	127.8	(75.7-202.0)	Female	2	4.1	nc	(nc-nc)
Female	14	15.3	91.2	(49.8-153.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.9	nc	(nc-nc)
Male	6	3.1	193.5	(70.6-421.1)	Female	3	4.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	42	45.3	92.7	(66.8-125.3)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.8	nc	(nc-nc)
Male	6	6.0	100.7	(36.8-219.3)	<u>Testis</u>				
Female	2	3.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	5	6.0	82.9	(26.7-193.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	4.1	nc	(nc-nc)	Female	8	9.5	84.5	(36.4-166.4)
Female	4	3.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	142	156.3	90.8	(76.5-107.1)
Male	3	3.3	nc	(nc-nc)	Female	140	149.8	93.4	(78.6-110.3)
Female	2	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	22.1	99.4	(62.3-150.6)					
Female	21	22.3	94.1	(58.2-143.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	21.2	80.1	(46.7-128.3)	Male	10	13.7	73.2	(35.1-134.7)
Female	8	8.8	90.5	(39.0-178.3)	Female	7	11.3	62.0	(24.8-127.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.9	nc	(nc-nc)	Male	5	3.5	143.2	(46.1-334.2)
Female	4	3.5	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	11	12.0	91.8	(45.7-164.2)
Female	92	81.4	113.0	(91.1-138.6)	Female	11	10.9	100.7	(50.2-180.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.0	201.1	(73.4-437.8)	Male	12	8.3	144.4	(74.5-252.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	25.7	93.5	(59.9-139.2)	Female	8	8.1	98.7	(42.5-194.5)
Female	28	30.1	93.0	(61.8-134.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	6.8	88.2	(32.2-192.0)
Male	9	5.5	164.3	(75.0-312.0)	Female	9	8.6	105.1	(48.0-199.6)
Female	0	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	70	79.0	88.6	(69.0-111.9)
Male	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.4	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.6	nc	(nc-nc)
Male	8	11.1	72.3	(31.1-142.5)	<u>Testis</u>				
Female	7	6.9	102.0	(40.9-210.3)	Male	0	2.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	3.2	187.7	(68.6-408.6)	Male	5	4.3	115.8	(37.3-270.3)
Female	1	1.0	nc	(nc-nc)	Female	7	13.4	52.4	(21.0-108.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	7.7	nc	(nc-nc)	Female	18	18.4	97.7	(57.8-154.3)
Female	5	6.4	78.2	(25.2-182.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	280	281.9	99.3	(88.0-111.7)
Male	6	6.0	99.7	(36.4-217.1)	Female	275	295.0	93.2	(82.5-104.9)
Female	4	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	57	38.2	149.2	(113.0-193.3)					
Female	34	41.5	82.0	(56.8-114.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.2	75.7	(30.3-156.1)	Male	6	6.7	89.1	(32.5-193.9)
Female	3	3.0	nc	(nc-nc)	Female	2	5.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	4	1.7	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
Female	42	39.4	106.7	(76.9-144.3)	Female	2	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	12.3	98.0	(50.6-171.1)	Female	4	3.6	nc	(nc-nc)
Female	9	10.7	84.3	(38.5-160.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.7	nc	(nc-nc)	Male	37	39.0	95.0	(66.9-130.9)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.9	nc	(nc-nc)	Male	7	1.3	519.5	(208.1-1070.3)
Female	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	5.7	nc	(nc-nc)	Female	9	8.7	103.8	(47.4-197.1)
Female	1	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Female</u>				
Male	1	1.6	nc	(nc-nc)	Male	115	135.9	84.6	(69.9-101.6)
Female	0	0.4	nc	(nc-nc)	Female	131	126.6	103.5	(86.5-122.8)
<u>Leukemia</u>					<u>Male</u>				
Male	4	3.7	nc	(nc-nc)	<u>Female</u>				
Female	2	2.5	nc	(nc-nc)	<u>Male</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Female</u>				
Male	3	3.2	nc	(nc-nc)	<u>Male</u>				
Female	1	0.9	nc	(nc-nc)	<u>Female</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	10	17.3	57.8	(27.7-106.3)	<u>Female</u>				
Female	16	16.1	99.1	(56.6-160.9)	<u>Male</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.9	101.8	(37.2-221.5)	Male	3	4.2	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	4	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	27	28.2	95.8	(63.1-139.4)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	7.5	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Female	7	9.3	75.6	(30.3-155.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.0	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	23	24.3	94.6	(60.0-142.0)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.1	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.4	nc	(nc-nc)	Male	4	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	5	4.8	103.9	(33.5-242.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.4	nc	(nc-nc)	Female	6	6.4	93.5	(34.2-203.6)
Female	1	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	87	85.3	102.0	(81.7-125.8)
Male	0	2.0	nc	(nc-nc)	Female	92	99.4	92.5	(74.6-113.5)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	11.2	143.3	(81.9-232.7)					
Female	16	14.5	110.6	(63.2-179.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.0	70.9	(22.9-165.6)	Male	3	4.3	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.2	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.7	187.6	(75.2-386.6)
Female	31	28.5	108.8	(73.9-154.4)	Female	3	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	8.2	157.8	(83.9-269.9)	Female	5	2.9	169.8	(54.7-396.3)
Female	7	12.5	56.2	(22.5-115.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.3	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	Female	6	3.6	166.4	(60.8-362.2)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	25	25.7	97.1	(62.8-143.3)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.5	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.4	nc	(nc-nc)	Female	5	6.4	78.6	(25.3-183.5)
Female	2	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	85	90.7	93.7	(74.8-115.8)
Male	1	2.0	nc	(nc-nc)	Female	113	110.5	102.3	(84.3-122.9)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	12.7	55.0	(22.0-113.2)					
Female	16	17.0	94.0	(53.7-152.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.3	123.1	(56.2-233.7)	Male	5	5.2	95.4	(30.8-222.7)
Female	1	3.0	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	4.5	222.0	(106.3-408.3)
Female	30	33.7	89.0	(60.0-127.0)	Female	7	4.0	174.3	(69.8-359.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	9.3	85.8	(37.0-169.2)	Female	4	3.2	nc	(nc-nc)
Female	12	10.2	118.0	(60.9-206.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	2.2	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	27	34.0	79.3	(52.3-115.4)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	11	4.5	243.5	(121.4-435.7)	Male	2	1.8	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.3	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	2.7	nc	(nc-nc)	Male	6	1.8	324.7	(118.6-706.8)
Female	4	2.3	nc	(nc-nc)	Female	9	6.0	149.4	(68.2-283.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	2.5	203.2	(65.5-474.1)	Female	6	7.7	78.3	(28.6-170.4)
Female	0	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	21	14.4	145.9	(90.3-223.0)	Male	128	109.9	116.4	(97.1-138.5)
Female	21	15.7	133.9	(82.8-204.6)	Female	121	113.7	106.4	(88.3-127.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	8.2	159.1	(84.6-272.1)	Male	12	5.6	213.6	(110.2-373.1)
Female	0	2.5	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	1.7	418.4	(167.6-862.0)	Male	4	1.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.0	161.6	(69.6-318.4)
Female	36	30.2	119.1	(83.4-164.9)	Female	4	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	10.4	143.7	(80.3-237.0)	Female	8	2.8	283.6	(122.1-558.9)
Female	9	8.4	107.3	(49.0-203.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.7	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	30	31.9	94.2	(63.5-134.4)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	1	4.6	nc	(nc-nc)	<u>Testis</u>				
Female	5	2.4	209.6	(67.5-489.0)	Male	1	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	7	5.7	123.1	(49.3-253.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.2	188.1	(68.7-409.3)	Female	10	7.0	143.8	(68.9-264.5)
Female	2	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	125	114.0	109.7	(91.3-130.7)
Male	3	2.5	nc	(nc-nc)	Female	108	99.5	108.6	(89.1-131.1)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	14.8	40.5	(14.8-88.1)					
Female	9	13.4	67.4	(30.7-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	8.6	58.2	(18.7-135.7)	Male	3	5.3	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	34	28.4	119.8	(83.0-167.5)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	6	3.2	188.7	(68.9-410.8)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	7	10.0	70.0	(28.0-144.1)	<u>Ovary</u>				
Female	6	9.7	61.7	(22.5-134.3)	Female	1	2.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	25	32.5	76.8	(49.7-113.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	5	2.4	211.9	(68.3-494.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	6	4.3	139.0	(50.8-302.7)
Male	2	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	7	6.5	107.2	(42.9-220.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.3	nc	(nc-nc)	Male	80	111.8	71.5	(56.7-89.1)
Female	0	0.8	nc	(nc-nc)	Female	87	99.6	87.4	(70.0-107.8)
<u>Lung and Bronchus</u>									
Male	11	15.8	69.7	(34.7-124.7)					
Female	11	14.4	76.6	(38.2-137.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	2.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	1.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	3	3.6	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	11	13.0	84.3	(42.0-150.9)
Male	0	0.3	nc	(nc-nc)	Female	5	9.8	51.3	(16.5-119.6)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.9	nc	(nc-nc)					
Female	0	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	14.0	135.3	(81.4-211.3)	Male	12	9.7	124.3	(64.2-217.2)
Female	5	4.7	107.3	(34.6-250.5)	Female	12	7.3	164.5	(84.9-287.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.9	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	8.4	130.3	(65.0-233.2)
Female	53	54.3	97.6	(73.1-127.7)	Female	8	6.2	129.0	(55.6-254.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.2	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	17.3	109.8	(66.1-171.4)	Female	10	5.0	201.0	(96.2-369.6)
Female	23	15.1	152.7	(96.8-229.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	4.6	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	Female	7	4.3	161.6	(64.8-333.1)
Female	3	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	64	55.8	114.7	(88.3-146.4)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	3.3	150.8	(48.6-351.8)
<u>Kidney & Renal Pelvis</u>					Female	0	1.7	nc	(nc-nc)
Male	10	8.1	123.5	(59.1-227.1)	<u>Testis</u>				
Female	5	4.4	113.9	(36.7-265.8)	Male	0	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.2	nc	(nc-nc)	Male	7	3.3	213.3	(85.5-439.5)
Female	1	0.6	nc	(nc-nc)	Female	15	10.0	149.7	(83.7-246.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.3	94.3	(30.4-220.1)	Female	13	12.2	106.9	(56.8-182.7)
Female	5	3.7	136.9	(44.1-319.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	208	196.3	105.9	(92.0-121.4)
Male	4	4.4	nc	(nc-nc)	Female	207	179.8	115.1	(100.0-131.9)
Female	1	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	26.5	86.8	(55.0-130.2)					
Female	23	25.1	91.6	(58.0-137.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	9.6	115.0	(57.3-205.8)	Male	4	6.9	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	7	5.0	140.2	(56.2-288.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	5.9	nc	(nc-nc)
Female	47	36.0	130.5	(95.9-173.5)	Female	9	4.0	226.6	(103.4-430.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	12.0	191.0	(121.0-286.6)	Female	3	3.3	nc	(nc-nc)
Female	8	9.2	86.6	(37.3-170.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	2.8	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.9	nc	(nc-nc)	Female	51	41.2	123.9	(92.2-162.9)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	6	5.8	102.9	(37.6-223.9)	Female	1	1.0	nc	(nc-nc)
Female	6	2.8	216.2	(78.9-470.5)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	1.6	nc	(nc-nc)	Female	17	7.3	233.0	(135.6-373.0)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	6	3.6	167.3	(61.1-364.1)	Female	3	2.5	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	3.1	nc	(nc-nc)	Male	151	139.5	108.2	(91.7-126.9)
Female	2	0.8	nc	(nc-nc)	Female	161	116.6	138.1	(117.6-161.2)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	23	18.6	123.8	(78.5-185.8)					
Female	18	15.2	118.5	(70.2-187.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.4	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	17	12.3	138.4	(80.6-221.6)	Female	1	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	4.0	124.6	(40.2-290.9)	Female	0	1.2	nc	(nc-nc)
Female	5	4.1	123.3	(39.7-287.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	11	12.4	89.0	(44.4-159.3)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	5.9	84.3	(27.2-196.7)	Male	37	44.3	83.5	(58.8-115.1)
Female	7	6.3	110.3	(44.2-227.4)	Female	44	42.7	103.1	(74.9-138.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.5	93.6	(37.5-193.0)	Male	10	5.4	186.2	(89.2-342.5)
Female	0	1.5	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	4.6	129.4	(47.3-281.7)
Female	23	19.4	118.6	(75.2-178.0)	Female	3	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	9.7	51.7	(16.6-120.5)	Female	2	1.7	nc	(nc-nc)
Female	8	4.9	164.2	(70.7-323.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.5	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	29	32.0	90.7	(60.8-130.3)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.5	nc	(nc-nc)
Male	3	4.5	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.8	nc	(nc-nc)	Female	5	4.4	113.7	(36.6-265.3)
Female	2	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	91	109.1	83.4	(67.1-102.4)
Male	3	2.5	nc	(nc-nc)	Female	59	61.1	96.6	(73.5-124.6)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	14.2	nc	(nc-nc)					
Female	2	7.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	26.3	178.6	(131.2-237.5)	Male	27	14.7	184.0	(121.2-267.7)
Female	9	10.1	88.9	(40.6-168.8)	Female	28	10.7	261.6	(173.8-378.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	12	12.7	94.5	(48.8-165.1)
Female	95	82.5	115.2	(93.2-140.8)	Female	13	12.0	108.2	(57.5-185.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.5	nc	(nc-nc)	Male	7	8.2	85.7	(34.4-176.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	28.9	83.0	(53.2-123.5)	Female	9	8.3	108.4	(49.5-205.7)
Female	36	32.8	109.9	(76.9-152.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	8.2	97.6	(42.0-192.4)
Male	5	6.2	80.2	(25.8-187.2)	Female	13	9.7	133.7	(71.1-228.7)
Female	2	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	117	89.4	130.9	(108.3-156.9)
Male	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	5	5.7	87.3	(28.1-203.8)
<u>Kidney & Renal Pelvis</u>					Female	5	3.8	129.9	(41.9-303.1)
Male	8	11.8	67.7	(29.2-133.5)	<u>Testis</u>				
Female	6	7.6	79.4	(29.0-172.8)	Male	3	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.6	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	2	10.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	8.4	95.5	(41.1-188.3)	Female	18	19.0	94.5	(56.0-149.4)
Female	4	6.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	369	316.7	116.5	(104.9-129.0)
Male	6	6.3	95.2	(34.7-207.1)	Female	319	311.7	102.3	(91.4-114.2)
Female	1	2.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	46	47.2	97.4	(71.3-129.9)					
Female	35	50.2	69.7	(48.5-96.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.1	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	22	18.7	117.8	(73.8-178.3)	Female	1	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	5.1	157.7	(67.9-310.8)	Female	2	1.8	nc	(nc-nc)
Female	8	5.8	138.2	(59.5-272.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	22	18.8	116.8	(73.2-176.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.5	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.7	nc	(nc-nc)	Male	65	60.0	108.4	(83.7-138.2)
Female	0	0.2	nc	(nc-nc)	Female	58	65.2	89.0	(67.6-115.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	6	8.1	74.4	(27.2-161.9)	<u>All Sites / Types</u>				
Female	6	10.3	58.3	(21.3-126.8)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	66	58.4	113.0	(87.4-143.7)	Male	40	39.7	100.7	(71.9-137.1)
Female	25	23.1	108.3	(70.1-159.9)	Female	33	33.7	98.0	(67.4-137.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	12.1	132.4	(75.6-214.9)	Male	6	9.8	61.5	(22.5-133.9)
Female	9	10.5	85.6	(39.1-162.5)	Female	8	8.3	96.5	(41.5-190.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.7	nc	(nc-nc)	Male	31	34.6	89.5	(60.8-127.1)
Female	211	234.3	90.1	(78.3-103.1)	Female	34	29.7	114.5	(79.3-160.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	9.4	53.1	(17.1-123.9)	Male	27	24.4	110.5	(72.8-160.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	93	71.7	129.7	(104.7-158.9)	Female	29	22.7	127.5	(85.4-183.1)
Female	78	78.6	99.2	(78.4-123.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	24	19.1	125.9	(80.6-187.4)
Male	16	15.5	103.0	(58.8-167.2)	Female	23	22.1	104.0	(65.9-156.1)
Female	6	4.7	127.8	(46.7-278.2)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	212	223.6	94.8	(82.5-108.5)
Male	6	5.8	103.8	(37.9-225.9)	<u>Stomach</u>				
Female	2	4.5	nc	(nc-nc)	Male	14	13.7	102.5	(56.0-172.0)
<u>Kidney & Renal Pelvis</u>					Female	7	9.1	76.6	(30.7-157.9)
Male	31	32.5	95.4	(64.8-135.5)	<u>Testis</u>				
Female	22	19.5	113.1	(70.8-171.2)	Male	14	9.9	141.3	(77.2-237.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	9.0	66.4	(24.3-144.6)	Male	10	13.7	73.3	(35.1-134.7)
Female	4	2.7	nc	(nc-nc)	Female	36	43.7	82.4	(57.7-114.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	22	22.2	99.1	(62.1-150.1)	Female	61	51.6	118.1	(90.4-151.7)
Female	17	17.8	95.4	(55.6-152.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	837	802.5	104.3	(97.3-111.6)
Male	15	17.4	86.0	(48.1-141.8)	Female	832	825.7	100.8	(94.0-107.9)
Female	9	6.3	143.6	(65.5-272.6)					
<u>Lung and Bronchus</u>									
Male	118	107.1	110.2	(91.2-132.0)					
Female	137	114.1	120.1	(100.8-142.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	0	3.2	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	2	10.3	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	5	7.0	71.7	(23.1-167.4)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.5	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	2.7	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.0	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	11	8.7	126.9	(63.3-227.1)
Male	1	0.2	nc	(nc-nc)	Female	9	8.0	112.4	(51.3-213.4)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.1	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	28.9	41.5	(21.4-72.5)	Male	41	18.0	227.8	(163.5-309.0)
Female	10	11.8	84.7	(40.5-155.7)	Female	22	14.5	152.2	(95.3-230.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	5.0	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
Female	5	4.6	107.9	(34.8-251.7)	Female	3	4.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	16	15.7	102.0	(58.3-165.6)
Female	106	107.1	99.0	(81.0-119.7)	Female	24	14.5	165.2	(105.8-245.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.7	nc	(nc-nc)	Male	4	10.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	34.1	105.7	(74.0-146.3)	Female	8	10.5	76.2	(32.8-150.1)
Female	43	39.2	109.8	(79.5-147.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	9.3	86.4	(37.2-170.2)
Male	7	7.4	94.1	(37.7-193.9)	Female	10	11.4	88.0	(42.1-161.9)
Female	1	2.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	104	108.3	96.0	(78.4-116.3)
Male	1	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.7	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	4.6	nc	(nc-nc)
Male	10	14.9	67.1	(32.1-123.4)	<u>Testis</u>				
Female	12	9.3	129.6	(66.9-226.4)	Male	5	2.6	192.3	(62.0-448.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.3	nc	(nc-nc)	Male	7	5.4	130.4	(52.2-268.7)
Female	0	1.3	nc	(nc-nc)	Female	20	16.5	121.4	(74.1-187.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	10.2	97.6	(46.7-179.5)	Female	22	24.1	91.4	(57.2-138.3)
Female	8	8.5	94.1	(40.5-185.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	331	378.5	87.5	(78.3-97.4)
Male	5	7.9	63.0	(20.3-147.0)	Female	387	389.2	99.4	(89.8-109.9)
Female	1	3.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	34	52.7	64.5	(44.7-90.2)					
Female	52	57.8	90.0	(67.2-118.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.2	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	10	9.2	108.8	(52.1-200.0)	Female	3	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.7	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	9	10.0	90.4	(41.3-171.6)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Female	6	2.2	272.0	(99.3-592.1)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	38	32.8	115.7	(81.9-158.8)
Male	2	0.8	nc	(nc-nc)	Female	31	29.2	106.3	(72.2-150.8)
Female	0	0.2	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	8	4.3	186.7	(80.4-367.8)	<u>Bladder, Urinary</u>				
Female	4	3.8	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Lung and Bronchus</u>					Female	0	0.7	nc	(nc-nc)
Male	8	4.3	186.7	(80.4-367.8)	<u>Brain and Other Nervous System</u>				
Female	4	3.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.2	128.4	(74.8-205.7)	Male	6	8.7	69.1	(25.2-150.4)
Female	6	4.3	138.6	(50.6-301.6)	Female	18	6.2	292.2	(173.1-461.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.4	205.2	(66.1-478.9)	Male	2	2.2	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.4	121.3	(55.4-230.3)
Female	50	45.0	111.1	(82.5-146.5)	Female	3	5.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	5	5.3	94.2	(30.4-219.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	15.6	89.5	(48.9-150.1)	Female	6	4.3	139.7	(51.0-304.1)
Female	17	14.1	120.7	(70.3-193.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	4.3	nc	(nc-nc)
Male	10	3.6	277.6	(132.9-510.6)	Female	6	4.1	147.8	(54.0-321.7)
Female	4	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	47	53.7	87.5	(64.3-116.3)
Male	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	5	3.0	164.8	(53.1-384.5)
<u>Kidney & Renal Pelvis</u>					Female	1	1.6	nc	(nc-nc)
Male	7	7.2	97.4	(39.0-200.6)	<u>Testis</u>				
Female	2	3.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	2.1	238.5	(76.9-556.6)	Male	6	2.8	215.8	(78.8-469.6)
Female	1	0.5	nc	(nc-nc)	Female	8	8.1	99.1	(42.7-195.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	4.6	nc	(nc-nc)	Female	12	10.3	116.5	(60.1-203.5)
Female	1	3.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	193	181.4	106.4	(91.9-122.5)
Male	3	3.9	nc	(nc-nc)	Female	201	155.6	129.2	(112.0-148.4)
Female	1	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	27	25.1	107.7	(70.9-156.7)					
Female	45	22.2	203.0	(148.1-271.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	19.9	105.7	(65.4-161.6)	Male	11	12.9	85.3	(42.5-152.6)
Female	6	7.8	76.9	(28.1-167.3)	Female	10	10.7	93.5	(44.8-172.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.8	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	6	3.3	183.2	(66.9-398.9)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	6	11.3	53.3	(19.5-115.9)
Female	65	79.3	82.0	(63.3-104.5)	Female	11	10.0	110.5	(55.1-197.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	12	7.8	153.7	(79.3-268.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	24.0	41.7	(20.0-76.7)	Female	11	7.6	144.0	(71.8-257.6)
Female	22	25.9	85.1	(53.3-128.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	5	5.1	97.4	(31.4-227.4)	Male	76	73.6	103.2	(81.3-129.2)
Female	3	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	1.5	nc	(nc-nc)	Male	8	2.4	337.5	(145.3-665.0)
Female	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	10.6	112.7	(58.2-196.9)	Female	14	17.9	78.1	(42.7-131.0)
Female	3	6.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.0	nc	(nc-nc)	Female	14	17.9	78.1	(42.7-131.0)
Female	0	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>All Sites / Types</u>				
Male	10	7.3	137.5	(65.8-252.9)	Male	255	264.5	96.4	(84.9-109.0)
Female	5	5.7	87.6	(28.2-204.4)	Female	232	275.5	84.2	(73.7-95.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	5.7	123.4	(49.4-254.3)	<u>All Sites / Types</u>				
Female	3	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	34	36.5	93.2	(64.5-130.3)	<u>All Sites / Types</u>				
Female	24	39.4	60.8	(39.0-90.5)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	5	7.8	63.9	(20.6-149.2)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.7	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	11	10.1	108.4	(54.0-193.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.8	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	4.4	nc	(nc-nc)	Female	33	34.8	94.9	(65.3-133.3)
Female	2	2.8	nc	(nc-nc)	Female	24	24.1	99.7	(63.8-148.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	14.4	83.3	(43.0-145.5)	Male	7	10.1	69.6	(27.9-143.4)
Female	5	5.0	99.5	(32.1-232.1)	Female	4	7.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.0	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	8.7	69.2	(25.3-150.7)
Female	53	58.2	91.1	(68.2-119.2)	Female	9	6.7	134.8	(61.5-256.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	17.8	106.6	(64.2-166.5)	Female	5	5.4	92.6	(29.8-216.1)
Female	12	16.4	73.2	(37.8-127.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	4.8	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	7	4.7	149.1	(59.7-307.2)
Female	0	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	69	62.0	111.2	(86.6-140.8)
Male	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.8	nc	(nc-nc)
Male	9	8.6	104.4	(47.6-198.2)	<u>Testis</u>				
Female	5	4.6	107.6	(34.7-251.2)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.4	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	15	10.3	145.6	(81.4-240.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	5.4	129.3	(51.8-266.4)	Female	15	13.4	112.3	(62.8-185.3)
Female	3	3.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	198	207.9	95.2	(82.4-109.4)
Male	6	4.7	128.4	(46.9-279.6)	Female	181	192.5	94.0	(80.8-108.7)
Female	3	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	27.7	68.5	(41.2-107.0)					
Female	20	27.0	74.0	(45.2-114.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	45.2	81.9	(57.7-112.9)	Male	19	28.1	67.6	(40.7-105.6)
Female	14	17.0	82.4	(45.0-138.2)	Female	18	22.7	79.2	(46.9-125.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	8.2	60.8	(19.6-141.9)	Male	4	7.3	nc	(nc-nc)
Female	5	7.4	67.9	(21.9-158.3)	Female	4	6.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	26	24.9	104.5	(68.2-153.1)
Female	150	160.1	93.7	(79.3-109.9)	Female	19	21.3	89.3	(53.8-139.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	6.1	146.5	(66.8-278.1)	Male	21	16.2	129.8	(80.3-198.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	52	53.4	97.4	(72.8-127.8)	Female	14	16.0	87.7	(47.9-147.2)
Female	61	57.5	106.2	(81.2-136.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	16	14.3	112.1	(64.0-182.0)
Male	11	10.9	100.7	(50.2-180.1)	Female	18	16.3	110.3	(65.3-174.3)
Female	5	3.4	147.0	(47.4-343.1)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	133	152.5	87.2	(73.0-103.4)
Male	2	3.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	3.1	nc	(nc-nc)	Male	7	10.3	68.2	(27.3-140.4)
<u>Kidney & Renal Pelvis</u>					Female	5	6.8	73.1	(23.6-170.6)
Male	18	22.3	80.6	(47.7-127.3)	<u>Testis</u>				
Female	13	13.5	96.0	(51.1-164.3)	Male	5	5.8	85.9	(27.7-200.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	6.3	143.3	(65.4-272.0)	Male	6	8.7	69.3	(25.3-150.9)
Female	1	1.9	nc	(nc-nc)	Female	15	28.2	53.3	(29.8-87.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	16.5	90.7	(50.7-149.6)	Female	43	35.9	119.8	(86.7-161.4)
Female	10	12.9	77.4	(37.1-142.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	508	573.8	88.5	(81.0-96.6)
Male	13	11.9	109.3	(58.2-187.0)	Female	546	579.2	94.3	(86.5-102.5)
Female	5	4.5	112.0	(36.1-261.4)					
<u>Lung and Bronchus</u>									
Male	69	79.9	86.3	(67.2-109.3)					
Female	89	81.1	109.8	(88.1-135.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	5.5	201.2	(100.3-360.1)	Male	6	3.9	153.4	(56.0-334.0)
Female	1	2.5	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	28	27.5	101.8	(67.7-147.2)	Female	2	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	6.9	86.8	(31.7-189.0)	Female	1	2.6	nc	(nc-nc)
Female	12	8.4	142.3	(73.4-248.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.8	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	27	21.9	123.1	(81.1-179.1)
Male	3	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	7	3.3	212.8	(85.3-438.6)	<u>Testis</u>				
Female	1	2.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	5.1	97.7	(31.5-228.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.1	nc	(nc-nc)	Female	5	6.3	78.9	(25.4-184.1)
Female	2	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	93	77.9	119.4	(96.4-146.3)
Male	2	1.8	nc	(nc-nc)	Female	80	94.3	84.8	(67.2-105.5)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	10.2	97.9	(46.9-180.1)					
Female	13	13.2	98.7	(52.5-168.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.0	90.7	(43.4-166.9)	Male	12	8.4	143.7	(74.2-251.1)
Female	3	3.4	nc	(nc-nc)	Female	8	6.7	120.2	(51.7-236.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.7	220.5	(80.5-480.0)	Male	1	2.0	nc	(nc-nc)
Female	5	2.1	242.3	(78.1-565.4)	Female	3	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	7.4	81.4	(29.7-177.3)
Female	63	48.9	128.8	(98.9-164.7)	Female	5	4.9	101.1	(32.6-235.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	14.9	87.5	(46.5-149.7)	Female	5	4.3	117.0	(37.7-273.1)
Female	11	11.7	94.2	(46.9-168.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.8	nc	(nc-nc)
Male	0	3.2	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	46	47.4	97.1	(71.1-129.5)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.3	nc	(nc-nc)
Male	5	7.1	70.4	(22.7-164.3)	<u>Testis</u>				
Female	1	3.6	nc	(nc-nc)	Male	5	1.9	265.0	(85.4-618.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	21	10.1	207.7	(128.5-317.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.7	106.6	(34.3-248.7)	Female	13	10.5	123.6	(65.7-211.3)
Female	2	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	138	166.2	83.0	(69.8-98.1)
Male	3	3.9	nc	(nc-nc)	Female	179	151.8	117.9	(101.3-136.5)
Female	2	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	9	20.7	43.4	(19.8-82.4)					
Female	18	18.9	95.3	(56.5-150.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.0	139.4	(55.8-287.2)	Male	1	3.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	22	15.1	145.9	(91.4-220.9)	Female	0	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	6.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	6	4.0	150.8	(55.1-328.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	1.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	1	0.4	nc	(nc-nc)	Female	15	20.4	73.5	(41.1-121.3)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	3	3.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.8	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.9	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	1.6	nc	(nc-nc)	Male	55	71.3	77.1	(58.1-100.4)
Female	0	0.3	nc	(nc-nc)	Female	50	48.1	104.1	(77.2-137.2)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	10	9.4	106.2	(50.8-195.3)					
Female	4	6.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	23.2	38.7	(17.7-73.5)	Male	10	15.2	65.6	(31.4-120.7)
Female	5	8.1	61.9	(19.9-144.3)	Female	8	11.8	67.9	(29.2-133.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.4	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	1	3.6	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	7	13.2	53.1	(21.3-109.3)
Female	80	85.9	93.1	(73.8-115.9)	Female	13	10.5	123.7	(65.8-211.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.3	nc	(nc-nc)	Male	10	9.3	107.8	(51.6-198.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	28.4	88.2	(57.0-130.2)	Female	8	8.3	96.6	(41.6-190.3)
Female	25	26.5	94.2	(61.0-139.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	7.5	146.2	(72.9-261.6)
Male	5	6.1	82.3	(26.5-192.2)	Female	7	7.6	91.7	(36.8-189.0)
Female	1	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	86	88.5	97.2	(77.7-120.0)
Male	0	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.4	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.0	nc	(nc-nc)
Male	10	12.4	80.5	(38.5-148.0)	<u>Testis</u>				
Female	6	7.2	83.7	(30.6-182.2)	Male	3	3.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	3.5	169.4	(61.8-368.7)	Male	3	4.9	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	17	15.4	110.4	(64.3-176.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	8.6	104.8	(47.8-199.0)	Female	22	20.2	109.0	(68.3-165.0)
Female	4	5.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	271	313.0	86.6	(76.6-97.5)
Male	5	6.7	75.1	(24.2-175.2)	Female	267	296.0	90.2	(79.7-101.7)
Female	1	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	44	42.2	104.2	(75.7-139.8)					
Female	38	42.3	89.9	(63.6-123.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	11.4	149.5	(87.0-239.3)	Male	9	8.1	111.8	(51.0-212.2)
Female	6	5.2	115.6	(42.2-251.6)	Female	8	7.7	104.4	(44.9-205.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.3	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	5	2.3	221.3	(71.3-516.4)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	9	6.9	131.2	(59.9-249.0)
Female	49	58.5	83.7	(61.9-110.7)	Female	11	6.9	160.2	(79.9-286.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	7	5.3	131.3	(52.6-270.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	14.3	111.8	(63.8-181.5)	Female	5	5.5	91.5	(29.5-213.6)
Female	16	17.0	94.1	(53.7-152.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.8	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	Female	6	4.9	122.8	(44.8-267.2)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	51	50.3	101.5	(75.5-133.4)
Male	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.9	nc	(nc-nc)
Male	8	6.9	116.4	(50.1-229.3)	<u>Testis</u>				
Female	5	4.7	106.4	(34.3-248.4)	Male	1	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.0	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	11	10.0	110.2	(54.9-197.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.2	nc	(nc-nc)	Female	14	13.8	101.5	(55.5-170.4)
Female	7	3.7	189.4	(75.9-390.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	205	166.4	123.2	(106.9-141.3)
Male	6	3.9	155.6	(56.8-338.7)	Female	202	195.1	103.5	(89.8-118.9)
Female	1	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	22.1	135.7	(91.5-193.7)					
Female	27	27.5	98.2	(64.7-142.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.5	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	8	8.3	96.0	(41.4-189.3)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.8	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	8	11.2	71.3	(30.7-140.6)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	3	1.5	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.9	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	40	36.1	110.9	(79.3-151.1)
Male	1	0.8	nc	(nc-nc)	Female	23	27.2	84.7	(53.7-127.1)
Female	1	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	4.9	122.1	(44.6-265.7)					
Female	3	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	17.3	115.5	(70.5-178.3)	Male	13	11.2	115.6	(61.5-197.7)
Female	4	7.5	nc	(nc-nc)	Female	17	9.2	185.0	(107.7-296.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.1	228.4	(91.5-470.5)	Male	3	2.9	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	9.7	103.2	(49.4-189.8)
Female	77	68.9	111.7	(88.2-139.6)	Female	13	9.2	141.0	(75.0-241.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.4	nc	(nc-nc)	Male	9	7.0	127.9	(58.4-242.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	21.2	47.3	(22.6-86.9)	Female	11	6.8	161.0	(80.3-288.1)
Female	27	25.1	107.6	(70.9-156.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.7	88.2	(28.4-205.9)
Male	2	4.6	nc	(nc-nc)	Female	13	7.2	180.6	(96.1-308.9)
Female	0	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	83	68.2	121.7	(96.9-150.8)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.0	nc	(nc-nc)
Male	9	9.4	95.9	(43.8-182.1)	<u>Testis</u>				
Female	4	5.9	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.7	nc	(nc-nc)	Male	5	3.6	140.6	(45.3-328.2)
Female	2	0.8	nc	(nc-nc)	Female	9	10.6	85.0	(38.8-161.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	6.1	179.8	(89.6-321.7)	Female	17	15.8	107.7	(62.7-172.4)
Female	5	5.3	94.7	(30.5-220.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	246	234.7	104.8	(92.1-118.7)
Male	5	5.1	98.2	(31.7-229.2)	Female	254	248.5	102.2	(90.0-115.6)
Female	3	2.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	29	32.2	90.0	(60.3-129.3)					
Female	27	36.2	74.6	(49.1-108.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.8	86.1	(42.9-154.1)	Male	10	8.5	117.6	(56.3-216.3)
Female	11	5.6	197.2	(98.3-352.9)	Female	11	7.5	146.5	(73.0-262.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.5	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.4	149.0	(74.3-266.7)
Female	63	53.9	117.0	(89.9-149.6)	Female	4	7.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	8	5.3	150.5	(64.8-296.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	15.8	94.9	(53.1-156.5)	Female	5	5.2	95.5	(30.8-222.9)
Female	21	19.3	108.7	(67.3-166.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	4.2	143.4	(52.4-312.1)
Male	1	3.4	nc	(nc-nc)	Female	5	5.4	92.3	(29.8-215.5)
Female	1	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	65	49.7	130.9	(101.0-166.8)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.3	nc	(nc-nc)
Male	7	7.0	99.4	(39.8-204.8)	<u>Testis</u>				
Female	5	4.4	112.9	(36.4-263.4)	Male	1	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.0	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	10	9.1	109.4	(52.4-201.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	4.8	167.8	(72.2-330.6)	Female	18	11.9	151.9	(90.0-240.0)
Female	7	4.3	164.2	(65.8-338.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	199	174.7	113.9	(98.6-130.9)
Male	2	3.8	nc	(nc-nc)	Female	208	191.7	108.5	(94.3-124.3)
Female	1	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	23.4	111.0	(72.5-162.7)					
Female	25	26.2	95.6	(61.8-141.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.4	96.2	(43.9-182.7)	Male	8	6.9	116.8	(50.3-230.1)
Female	5	3.2	154.7	(49.8-360.9)	Female	5	5.3	94.5	(30.5-220.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	6.0	133.8	(57.6-263.6)
Female	44	37.3	118.0	(85.8-158.5)	Female	5	4.3	115.4	(37.2-269.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	12.1	206.9	(133.8-305.4)	Female	1	3.5	nc	(nc-nc)
Female	17	11.6	146.3	(85.2-234.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.2	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	Female	8	3.1	255.8	(110.1-504.0)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	56	39.1	143.2	(108.2-186.0)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.3	nc	(nc-nc)
Male	7	5.8	120.4	(48.2-248.1)	<u>Testis</u>				
Female	5	2.9	173.5	(55.9-404.9)	Male	6	1.6	374.3	(136.7-814.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.6	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	6	7.1	84.3	(30.8-183.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.8	nc	(nc-nc)	Female	9	7.9	113.9	(52.0-216.3)
Female	3	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	178	137.2	129.7	(111.4-150.3)
Male	2	3.2	nc	(nc-nc)	Female	148	124.8	118.6	(100.2-139.3)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	17.7	118.9	(73.6-181.7)					
Female	23	15.9	144.8	(91.8-217.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	5.0	241.4	(124.6-421.6)	Male	1	4.2	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.6	140.1	(45.2-327.0)
Female	24	23.3	102.9	(65.9-153.1)	Female	1	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	6.9	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
Female	10	6.4	155.4	(74.4-285.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	1.5	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.8	nc	(nc-nc)	Female	35	23.0	152.1	(105.9-211.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	3	3.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	6	1.8	330.4	(120.6-719.1)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	3	0.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	2.1	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	5	1.5	329.2	(106.1-768.3)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	1.9	nc	(nc-nc)	Male	7	5.4	130.4	(52.2-268.6)
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	12	9.7	123.5	(63.8-215.8)	Female	88	80.2	109.8	(88.1-135.3)
Female	15	10.1	148.1	(82.9-244.4)	Female	94	76.6	122.7	(99.2-150.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.4	148.7	(47.9-346.9)	Male	6	2.3	259.9	(94.9-565.6)
Female	1	1.0	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	17	12.2	139.0	(81.0-222.6)	Female	3	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	4.3	117.0	(37.7-272.9)	Female	1	1.1	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.1	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	19	14.6	130.6	(78.6-203.9)
Male	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.3	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	0	3.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	59	48.2	122.3	(93.1-157.8)
Male	0	1.0	nc	(nc-nc)	Female	45	39.3	114.6	(83.6-153.3)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	6.4	109.3	(43.8-225.2)					
Female	6	5.4	111.1	(40.6-241.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	47.0	115.0	(86.4-150.0)	Male	14	34.4	40.7	(22.2-68.2)
Female	13	18.4	70.6	(37.5-120.7)	Female	14	31.5	44.4	(24.3-74.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	11.6	103.1	(53.2-180.1)	Male	12	8.1	148.0	(76.4-258.5)
Female	8	10.5	76.3	(32.8-150.3)	Female	13	6.7	195.0	(103.7-333.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.4	nc	(nc-nc)	Male	29	30.5	95.1	(63.7-136.6)
Female	187	208.1	89.9	(77.4-103.7)	Female	24	25.2	95.2	(61.0-141.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	9.2	183.9	(107.1-294.5)	Male	20	21.6	92.7	(56.6-143.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	70	60.9	115.0	(89.6-145.3)	Female	14	20.0	70.0	(38.2-117.5)
Female	76	62.1	122.3	(96.4-153.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	18	15.5	115.8	(68.6-183.0)
Male	11	12.8	85.9	(42.8-153.8)	Female	25	17.4	143.9	(93.1-212.4)
Female	4	3.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	227	183.1	124.0	(108.4-141.2)
Male	4	6.1	nc	(nc-nc)	<u>Stomach</u>				
Female	9	5.3	171.2	(78.1-325.0)	Male	21	11.4	183.8	(113.7-281.0)
<u>Kidney & Renal Pelvis</u>					Female	7	7.1	99.1	(39.7-204.2)
Male	17	28.2	60.3	(35.1-96.6)	<u>Testis</u>				
Female	14	17.0	82.3	(44.9-138.0)	Male	8	10.8	73.8	(31.8-145.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	15	7.5	199.8	(111.8-329.6)	Male	14	13.0	107.6	(58.8-180.6)
Female	3	2.4	nc	(nc-nc)	Female	42	44.6	94.3	(67.9-127.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	21	20.3	103.6	(64.1-158.3)	Female	44	46.6	94.4	(68.6-126.7)
Female	18	16.2	111.3	(65.9-175.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	746	677.8	110.1	(102.3-118.3)
Male	27	15.0	180.5	(118.9-262.6)	Female	700	717.9	97.5	(90.4-105.0)
Female	10	5.3	188.8	(90.4-347.2)					
<u>Lung and Bronchus</u>									
Male	99	85.8	115.3	(93.7-140.4)					
Female	86	94.5	91.0	(72.8-112.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	6.7	148.7	(71.2-273.6)	Male	6	4.6	131.4	(48.0-286.0)
Female	4	2.7	nc	(nc-nc)	Female	9	3.7	244.6	(111.6-464.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	25	27.5	91.0	(58.9-134.3)	Female	6	3.4	174.2	(63.6-379.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	8.2	121.9	(58.3-224.1)	Female	0	2.7	nc	(nc-nc)
Female	15	8.5	176.9	(98.9-291.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.2	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	28.7	115.1	(79.2-161.6)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	6	4.6	129.8	(47.4-282.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.4	nc	(nc-nc)	Female	3	6.6	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	109	95.4	114.2	(93.8-137.8)
Male	2	2.2	nc	(nc-nc)	Female	104	95.5	108.9	(89.0-132.0)
Female	1	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	13.1	152.4	(93.0-235.3)					
Female	19	14.2	133.6	(80.4-208.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	12.1	82.7	(39.6-152.1)	Male	4	8.0	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	Female	6	6.5	92.6	(33.8-201.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.3	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.0	nc	(nc-nc)
Female	47	46.4	101.2	(74.4-134.6)	Female	2	5.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	0	5.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	15.0	46.6	(18.7-96.1)	Female	1	4.5	nc	(nc-nc)
Female	15	15.2	98.7	(55.2-162.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	4.0	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	Female	6	4.3	138.7	(50.6-301.8)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	38	45.1	84.3	(59.6-115.7)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.7	nc	(nc-nc)
Male	9	6.5	138.1	(63.0-262.2)	<u>Testis</u>				
Female	2	3.9	nc	(nc-nc)	Male	5	1.6	311.5	(100.4-727.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.8	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	8.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	4.6	131.5	(48.0-286.3)	Female	12	10.5	113.9	(58.8-198.9)
Female	3	3.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	136	163.1	83.4	(70.0-98.7)
Male	5	3.6	139.3	(44.9-325.2)	Female	145	162.6	89.2	(75.3-104.9)
Female	0	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	29	21.9	132.7	(88.8-190.5)					
Female	33	23.3	141.9	(97.6-199.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	8.9	146.1	(77.7-249.9)	Male	10	5.0	198.7	(95.1-365.4)
Female	1	3.7	nc	(nc-nc)	Female	8	3.8	208.5	(89.8-410.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	37	28.1	131.6	(92.6-181.4)	Female	2	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	0.9	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	10.0	169.3	(98.5-271.0)	Female	2	2.9	nc	(nc-nc)
Female	13	12.7	102.2	(54.4-174.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.8	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	Female	5	3.6	137.2	(44.2-320.1)
Female	2	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	36	29.5	122.1	(85.5-169.0)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.5	nc	(nc-nc)
Male	6	4.0	150.0	(54.8-326.5)	<u>Testis</u>				
Female	3	2.6	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	6	3.6	164.4	(60.0-357.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	3.0	232.7	(93.2-479.4)	Female	9	6.1	148.6	(67.8-282.1)
Female	2	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	126	107.6	117.1	(97.6-139.5)
Male	0	2.1	nc	(nc-nc)	Female	121	110.0	110.0	(91.3-131.5)
Female	3	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	15.5	64.4	(30.8-118.4)					
Female	11	16.6	66.1	(33.0-118.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	47.2	82.7	(58.8-113.0)	Male	21	30.4	69.1	(42.8-105.7)
Female	16	18.2	87.7	(50.1-142.5)	Female	19	24.7	76.9	(46.3-120.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	8.9	123.4	(61.5-220.8)	Male	5	7.7	65.1	(21.0-151.9)
Female	6	7.7	78.0	(28.5-169.9)	Female	3	6.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.4	nc	(nc-nc)	Male	22	26.7	82.5	(51.7-125.0)
Female	166	175.8	94.4	(80.6-109.9)	Female	22	23.0	95.6	(59.9-144.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.7	74.2	(23.9-173.1)	Male	10	18.1	55.4	(26.5-101.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	47	56.6	83.0	(61.0-110.4)	Female	18	17.1	105.4	(62.5-166.7)
Female	59	61.7	95.6	(72.8-123.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	15.1	92.8	(50.7-155.8)
Male	13	12.0	108.8	(57.9-186.0)	Female	21	17.5	119.7	(74.1-183.0)
Female	1	3.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	135	170.5	79.2	(66.4-93.7)
Male	5	3.9	127.3	(41.0-297.1)	<u>Stomach</u>				
Female	6	3.1	190.7	(69.6-415.0)	Male	8	10.9	73.4	(31.6-144.7)
<u>Kidney & Renal Pelvis</u>					Female	8	7.2	110.9	(47.7-218.5)
Male	19	24.6	77.1	(46.4-120.5)	<u>Testis</u>				
Female	11	14.8	74.4	(37.1-133.1)	Male	4	6.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	6.9	129.6	(59.1-246.1)	Male	3	9.7	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	Female	26	30.7	84.7	(55.3-124.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	17.4	103.5	(61.3-163.6)	Female	38	38.6	98.6	(69.7-135.3)
Female	14	13.6	103.1	(56.3-173.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	524	620.9	84.4	(77.3-91.9)
Male	7	13.1	53.5	(21.5-110.3)	Female	562	628.0	89.5	(82.2-97.2)
Female	5	4.8	103.2	(33.3-240.9)					
<u>Lung and Bronchus</u>									
Male	91	85.1	106.9	(86.1-131.3)					
Female	64	89.1	71.9	(55.3-91.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;